ERBB2 and triple-negative breast carcinoma: A recent study focused on the role of FGF13 expression in triple negative breast cancer (TNBC) (ER-, progesterone receptor-, and human epidermal growth factor receptor 2 (HER2/ERBB2)-negative breast cancer), an aggressive subtype of breast cancer where FGF13 expression was associated with relapse but was not increased in primary breast tumors.